Abstract:Abstract Background: Nanoparticles for over forty years have been the subject of a large number of physical and bioscience research . In the last decade use of these particles in medicine has gone from theoretical to clinical trials. Passive targeting of metal-based nanoparticles takes advantage of inherent abnormalities in tumor vasculature allowing accumulation in solid tumors through a process known as the ‘‘enhanced permeability and retention’’ (EPR) effect. In animal tumor implant models, combination of gold and silicone nanoparticle (GSN) and exposure of tumors to laser light (at 808nm) generated enough heat to cause tumor cell death. Mast cell tumors (MCT) are the most common skin tumor in dogs, with an estimate of MCT being roughly 20% of canine skin tumors. The goal of this pilot study is to evaluate nanoparticle and laser tumor thermal ablation on low grade canine MCT model. Results: 38 dogs with 44 mast cell tumors were enrolled in this prospective pilot study. All control tumors and those biopsied prior to laser therapy were found to be low grade MCT by histopathology (two grade method). After random number generation 8 dogs were assigned to control group and 30 dogs were assigned to treatment group. Treatment group had 36 total tumors and control group had 8 tumors present at time of enrollment. Treatment dogs had a 100% response rate, with 94% achieving clinical remission (34 tumors). Recurrence rate was 17% in those tumors achieving clinical remission. Mean progression free time (PFT) for the treatment group was 552 days and mean PFT for the control group was 1095 days. Conclusion: In conclusion results of this study suggest that photothermal ablation using gold-silicone nanoparticles and exposure to near infrared light (808 nm) provides an effective local therapy of low-grade mast cell tumors. Median progression free time and survival was not reached in our treatment group. Suggesting that long term tumor control is possible with PTA that potentially equals surgery when margins are narrow (<0.3cm) or incomplete. PTA appears to have better and more durable MCT responses than either radiation therapy and electrochemotherapy when used as sole therapies.

Wavefield modeling and array processing. II. Algorithms

Tumor Grade and Mitotic Count Are Prognostic for Dogs with Cutaneous Mast Cell Tumors Treated with Surgery and Adjuvant or Neoadjuvant Vinblastine Chemotherapy

Difference in outcome between curative intent vs marginal excision as a first treatment in dogs with oral malignant melanoma and the impact of adjuvant CSPG4‐DNA electrovaccination: A retrospective study on 155 cases

Investigation of the Theragnostic Role of KIT Expression for the Treatment of Canine Mast Cell Tumors with Tyrosine Kinase Inhibitors

[Perioperative management for laryngotracheal reconstruction during the period of anticoagulant therapy].

VEGF concentration from plasma-activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model

The Use of Sentinel Lymph Node Mapping for Canine Mast Cell Tumors

Oxidative Status and Lipid Metabolism Analytes in Dogs with Mast Cell Tumors: A Preliminary Study

Effects of Electrochemotherapy with Cisplatin and Peritumoral IL-12 Gene Electrotransfer on Canine Mast Cell Tumors: a Histopathologic and Immunohistochemical Study

Genetic Changes in Mastocytes and Their Significance in Mast Cell Tumor Prognosis and Treatment

Expression of Carboxypeptidase A3 and Tryptase as Markers for Lymph Node Metastasis of Canine Cutaneous Mast Cell Tumors

Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone

Association of Systemic Inflammatory and Immune Indices With Survival in Canine Patients With Oral Melanoma, Treated With Experimental Immunotherapy Alone or Experimental Immunotherapy Plus Metronomic Chemotherapy

Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate

Intensive Multimodal Chemotherapy in a Dog Suffering from Grade III/Stage IV Solid Mammary Carcinoma

A Pilot Study Using Nanoparticles and Laser Induced Photothermal Ablation to Treat Low Grade Canine Mast Cell Tumors: Evaluation of Efficacy and Safety

Tumor Immune Microenvironment and Its Clinicopathological and Prognostic Associations in Canine Splenic Hemangiosarcoma

An Abscopal Effect on Lung Metastases in Canine Mammary Cancer Patients Induced by Neoadjuvant Intratumoral Immunotherapy with Cowpea Mosaic Virus Nanoparticles and Anti-Canine PD-1

COMMD1 regulates the delta epithelial sodium channel (δENaC) through trafficking and ubiquitination.

Systematic Review of Methods and Prognostic Value of Mitotic Activity. Part 2: Canine Tumors

Standardized approach for evaluating tumor infiltrating lymphocytes in canine mammary carcinoma: Spatial distribution and score as relevant features of tumor malignancy